Navigation Links
Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009
Date:8/5/2009

NANJING, China, Aug. 5 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that it intends to release its 2009 second quarter results on Monday, August 17, 2009, after the market closes in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2009 second quarter results on Tuesday, August 18, at 8 a.m. ET (Tuesday, August 18, at 8 p.m. Beijing/Hong Kong time).

    To access the conference call, please dial:

    United States toll-free:   +1.866.510.0705
    International:             +1.617.597.5363
    North China toll-free:     10.800.152.1490
    South China toll-free:     10.800.130.0399
    China toll free / Netcom:  10 800 852 1490
    Hong Kong:                 +852.3002.1672

Please ask to be connected to Q2 2009 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 78992895.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .


    Following the earnings conference call, an archive of the call will be
available by dialing:

    United States toll-free:     +1.888.286.8010
    International:               +1.617.801.6888

The passcode for replay participants is: 77592594. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
2. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
3. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
4. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
5. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
6. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
7. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
8. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
11. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... decision-makers are preparing for how his administration could impact the employee benefits industry. ... what changes are most likely to make it through Congress. His discussion will ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion dollar ... shops –can’t help but be heartened by the industry’s current surge. But another thing ... as “skunk smell.” At last they can simply, safely and effectively end their ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: